Table 1 Background of the patients with type 2 diabetes mellitus (n = 307)
| Â | Anagliptin | Sitagliptin | P |
|---|---|---|---|
n (M/F) | 148 (89/59) | 159 (93/66) | 0.77 |
Age (years) | 68 ± 9 | 68 ± 9 | 0.91 |
Body mass index | 26.7 ± 3.9 | 25.8 ± 3.6 | 0.04 |
Waist circumference (cm) | 94.2 ± 11.1 | 92.7 ± 9.8 | 0.24 |
Smoking habit | 71 (48) | 92 (58) | 0.08 |
Alcohol drinking habit | 58 (39) | 67 (42) | 0.60 |
Diagnosis | |||
 Hypertension | 117 (79) | 116 (73) | 0.21 |
 Coronary artery disease | 68 (46) | 71 (45) | 0.82 |
 Stroke | 22 (15) | 24 (15) | 0.96 |
Medication | |||
 Dipeptidyl peptidase-4 inhibitora | 122 (82) | 128 (81) | 0.66 |
 Biguanide | 74 (50) | 71 (45) | 0.35 |
 Thiazolidinedione | 22 (15) | 29 (18) | 0.43 |
 α glucosidase inhibitor | 19 (13) | 27 (17) | 0.31 |
 Sulfonylurea | 41 (28) | 32 (20) | 0.12 |
 Glinide | 7 (5) | 2 (1) | 0.09 |
 Sodium–glucose cotransporter 2 inhibitor | 25 (17) | 16 (10) | 0.08 |
 Insulin | 12 (8) | 13 (8) | 0.98 |
 Statin | 148 (100) | 159 (100) | – |
 Strong statinb | 118 (80) | 121 (76) | 0.44 |
 Ezetimibe | 16 (11) | 11 (7) | 0.23 |
 Fibrate | 9 (6) | 7 (4) | 0.51 |
 Eicosapentaenoic acid | 16 (11) | 13 (8) | 0.43 |
 Angiotensin II receptor blocker | 75 (51) | 80 (50) | 0.95 |
 Angiotensin-converting enzyme inhibitor | 18 (12) | 10 (6) | 0.07 |
 Calcium channel blocker | 72 (49) | 68 (43) | 0.30 |
 β blocker | 35 (24) | 38 (24) | 0.96 |
 Diuretic | 24 (16) | 20 (13) | 0.36 |
 Mineralocorticoid receptor antagonist | 6 (4) | 6 (4) | 0.90 |